Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjusted carboplatin dosing pharmacokinetics study
NL-OMON44328Phase 4Active, not recruiting
- Sponsor
- Ziekenhuisapotheek
- Start
- Sep 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carboplatin in Nonhematologic neoplasms, bronchial carcinoma and ovarian cancer, sponsored by Ziekenhuisapotheek. Primary endpoints: Mean prediction error of carboplatin AUC and Mean absolute prediction error of carboplatin AUC. Started Sep 2014; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
Nonhematologic neoplasmsbronchial carcinomaovarian cancer
Beyond the preview
Go deeper on NL-OMON44328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44328.